



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50206-014002
	Serial No.	10/654,763
	Applicant	Nicholas P. Barker et al.
	Filing Date	September 3, 2003
	Group	1616
	IDS Filed	June 23, 2004
	Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
BD/H	4,647,454	03/03/87	Cymbalista	_____	_____	
↓	5,349,001	09/20/94	Greenwald et al.	_____	_____	
↓	5,359,030	10/25/94	Ekwuribe	_____	_____	
↓	5,382,657	01/17/95	Karasiewicz et al.	_____	_____	
↓	5,446,090	08/29/95	Harris	_____	_____	
↓	6,296,844	10/02/01	Takahashi	_____	_____	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
BD/H	WO 98/16255 A2	04/23/98	PCT	_____	_____	
↓	WO 00/66137 A1	11/9/00	PCT	_____	_____	
↓	WO 02/32414 A2	04/25/02	PCT	_____	_____	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

BD/H	Bailon et al., "Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α 2a for the treatment of hepatitis C," <i>Bioconjugate Chem.</i> 12:195-202 (2001).
↓	Burgess et al., "Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis," <i>Hepatology</i> 15:702-706 (1992).
↓	Cutrone et al., "Identification of critical residues in bovine IFNAR-1 responsible for interferon binding," <i>J. Biol. Chem.</i> 276:17140-17148 (2001).
↓	Dotzauer et al., "Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor," <i>J. Virology</i> 74:10950-10957 (2000).

EXAMINER Bruce D. Huns

DATE CONSIDERED 3/9/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50206-014002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Serial No.	10/654,763
				Applicant	Nicholas P. Barker et al.
				Filing Date	September 3, 2003
				Group	1616
				IDS Filed	June 23, 2004
				Customer No.	21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
B01A	Eisenberg et al., "Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations," <i>J. Hepatol.</i> 13:305-309 (1991).				
	Eto et al., "Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon," <i>Nature Medicine</i> 5:577-581 (1999).				
	Glue et al., "Pegylated interferon- α 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data," <i>Clinical Pharmacology & Therapeutics</i> 68:556-567 (2000).				
	Grace et al., "Structural and biologic characterization of pegylated recombinant IFN- α 2b," <i>J Interferon Cytokine Res.</i> 21:1103-1115 (2001).				
	Harvey et al., "Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm," <i>Mol. Microbiol.</i> 36:1059-1070 (2000).				
	Harvey et al., "Receptor-mediated endocytosis of <i>Neisseria gonorrhoeae</i> into primary human urethral epithelial cells: The role of the asialoglycoprotein receptor," <i>Mol. Microbiol.</i> 42:659-672 (2001).				
	Hirose et al., "Regulation of asialoglycoprotein receptor expression in proliferative state of hepatocytes," <i>Biochem. Biophys. Res. Communications</i> 287:675-681 (2001).				
	Karpusas et al., "The crystal structure of human interferon β at 2.2-Å resolution," <i>Proc. Natl. Acad. Sci. USA</i> 94:11813-11818 (1997).				
	Kasama et al., "Pharmacokinetics and biologic activities of human native and asialointerferon- β s," <i>J. Interferon Cytokine Res.</i> 15:407-415 (1995).				
	Lee et al., "Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin," <i>J. Biolog. Chem.</i> 258:199-202 (1983).				
	Mizuno et al., "Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma," <i>Liver</i> 13:80-85 (1993).				
	Monkarsh et al., "Positional isomers of monopegylated interferon α -2a: Isolation, characterization, and biological activity," <i>Anal. Biochem.</i> 247:434-440 (1997).				
	Nyman et al., "Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon- α 2b and interferon- α 14c produced by Sendai-virus-induced human peripheral blood leukocytes," <i>Eur. J. Biochem.</i> 253:485-493 (1998).				
EXAMINER	Bruce D. Gustin			DATE CONSIDERED	3/9/06
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					

Sheet 3 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50206-014002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.	10/654,763
				Applicant	Nicholas P. Barker et al.
				Filing Date	September 3, 2003
				Group	1616
				IDS Filed	June 23, 2004
				Customer No.	21559
(37 C.F.R. § 1.98(b))					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
B014	Pepinsky et al., "Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon- β -1a with preserved in vitro bioactivity," <i>J. Pharmacol. Exp. Ther.</i> 297:1059-1066 (2001).				
	Qin et al., "Interferon- β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice," <i>Proc. Natl. Acad. Sci. USA</i> 95:14411-14416 (1998).				
	Qin et al., "Human and mouse IFN- β gene therapy exhibits different anti-tumor mechanisms in mouse models," <i>Mol. Therapy</i> 4:356-364 (2001).				
	Schering-Plough Research Institute, "Toxicologist's Review of Pegylated Interferon- α 2b (PEG-IFN, PEG-INTRON)," December 19, 2000.				
	Tada et al., "Systemic IFN- β gene therapy results in long-term survival in mice with established colorectal liver metastases," <i>J. Clin. Invest.</i> 108:83-95 (2001).				
	Takahashi et al., "Acute hepatitis in rats expressing human hepatitis B virus transgenes," <i>Proc. Natl. Acad. Sci. USA</i> 92:1470-1474 (1995).				
	Treiber, "Systemic treatment of hepatocellular carcinoma," <i>Dig. Dis.</i> 19:311-323 (2001).				
	Trere et al., "The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells," <i>British J. Cancer</i> 81:404-408 (1999).				
	U.S. Food and Drug Administration, Product Approval Information: Peginterferon alfa-2b. May 28, 2002.				
	Uwatoku et al., "Asialoglycoprotein receptors on rat dendritic cells: possible roles for binding with kupffer cells and ingesting virus particles," <i>Arch. Histol. Cytol.</i> 64:223-232 (2001).				
	Wang et al., "Identification of the major positional isomer of pegylated interferon alpha-2b," <i>Biochem.</i> 39:10634-10640 (2000).				
EXAMINER	Bruce D. Lundy			DATE CONSIDERED 3/8/06	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					